CytoSorb®-bal végzett vértisztító eljárás
Cikk címe: CytoSorb®-bal végzett vértisztító eljárás
Szerzők: Dr. Hawchar Fatime, Prof. Dr. Molnár Zsolt
Intézmények: Szegedi Tudományegyetem, Aneszteziológiai és Intenzív Terápiás Intézet
Évfolyam: XVIII. évfolyam
Lapszám: 2019. / 04. lapszám
Oldal: 18-24
Rovat: KLINIKUM
Alrovat: INTENZÍV TERÁPIA
Absztrakt:
A szepszis előfordulása világszerte növekvő tendenciát mutat, és az egyik vezető kórházi halálokká vált. A kimenetel javítására évtizedek óta kutatott lehetőség az immunrendszer és ezzel együtt a gazdaszervezet fertőzésre adott válaszának modulációja, azonban ezek nem váltották be a hozzájuk fűzött reményeket. Ennek egyik legfőbb oka az, hogy ezek a kezelések ennek a bonyolult rendszernek csak egyes elemeit szándékoztak befolyásolni. Viszonylag új koncepcióként jelent meg a terápiában, hogy a szeptikus sokk korai szakaszában a szervezet fertőzésre adott diszregulált immunválasza következtében kialakuló „citokin vihar” befolyásolható lehet a ci – tokinek nagy mennyiségben történő extrakorporális vértisztító eljárással történő eliminációjával. Ennek legígéretesebb és mindössze néhány éve alkalmazott formája a CytoSorb® terápia. A jelen összefoglalóban a kezelés elméleti hátterét és a közelmúltban megjelent legfontosabb klinikai eredmények foglaljuk össze.
Abstract:
The incidence of sepsis has increased over the decades and it seems to be the single most important cause of hospitalization, which makes it a serious health economic issue worldwide. One of the more theoretical approaches to improve outcomes is the modulation of the immune system and the host’s response, which has been in the spotlight of research for decades. Hitherto, anti-inflammatory therapies, such as anti-cytokines, antioxidants, etc., have been tested but the results were disappointing. Nevertheless, modulating the “cytokine storm” that occurs in the early phase of septic shock as a result of a dysregulated immune response could provide some benefits by regaining the control between a pro-inflammatory and anti-inflammatory imbalance. One of the most promising therapeutic modalities in this field is the extracorporeal cytokine removal with CytoSorb®. The present review’s aim is to give the pathophysiological background and to summarize current result of clinical investigations.
XVIII. évfolyam
2019. / 04. lapszám / Május
| Szerző | Intézmény |
|---|---|
| Dr. Hawchar Fatime | Szegedi Tudományegyetem, Aneszteziológiai és Intenzív Terápiás Intézet |
| Prof. Dr. Molnár Zsolt | Aneszteziológiai és Intenzív Terápiás Intézet |
[1] Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo r: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000– 2012. JAMA. 2014;311:1308.
[2] Gaieski DF, Edwards JM, Kallan MJ, Carr BG: Bench – marking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167–74.
[3] Torio CM, Andrews rM: National inpatient hospital costs: the most expensive conditions by payer. HCUP Statistical Brief #160. Agency for Healthcare research and Quality, rockville, MD. 2013 http://www.hcup-us.ahrq.gov/reports/ statbriefs/sb160.pdf. Megtekintve 2018 nov 16.
[4] ProCESS Investigators: A randomized trial of protocolbased care for early septic shock. Process trial. N Engl J Med. 2014;370:1–11.
[5] Thiel P, Schmidt K, Mueller F, Ludewig K, Brunkhorst F, Gensichen J: The Jena Sepsis registry: a prospective observational registry for patients with severe sepsis or septic shock, supported by primary care. Infection. 2011; 39:S138–9.
[6] Alejandria M, Lansang M, Dans L, Mantaring JB III: Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst rev. 2013;(9):CD001090.
[7] Szakmany T, Hauser B, radermacher P: N-acetylcysteine for sepsis and systemic inflammatory response in adults. Cochrane Database Syst rev. 2012:CD006616.
[8] Lukaszewicz AC, Payen D: Purification methods: a way to treat severe acute inflammation related to sepsis? Crit Care. 2013;17:3–4.
[9] Harder J, Schröder JM, Gläser r: The skin surface as antimicrobial barrier: present concepts and future outlooks. Exp Dermatol. 2013;22:1–5.
[10] Baroni A, Buommino E, De Gregorio V, ruocco E, ruocco V, Wolf r: Structure and function of the epidermis related to barrier properties. Clin Dermatol. 2012;30:257–62.
[11] rudraraju r, Jones BG, Surman SL, Sealy rE, Thomas PG, Hurwitz JL: respiratory tract epithelial cells express retinaldehyde dehydrogenase ALDH1A and enhance IgA production by stimulated B cells in the presence of vitamin A. PLoS One. 2014;9:1–10.
[12] Pelaseyed T, Bergström JH, Gustafsson JK et al.: The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract. Immunol rev. 2014;260:8–20.
[13] Ghosh M: Secreted mucosal antimicrobials in the female reproductive tract that are important to consider for HIV prevention. Am J reprod Immunol. 2014;71:575–88.
[14] Kompoti M, Michopoulos A, Michalia M, Clouva-Molyvdas PM, Germenis AE, Speletas M: Genetic polymorphisms of innate and adaptive immunity as predictors of outcome in critically ill patients. Immunobiology. 2015;220:414–21.
[15] Zhang Q, raoof M, Chen Y et al.: Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–7.
[16] Hawchar F, Öveges N, Molnár Z.: Extracorporeal cytokine removal in septic shock. Springer Nature Switzerland AG, in J.-L. Vincent (ed), Annual Update in Intensive Care and Emergency Medicine 2019, p559-570, https://doi.org/ 10.1001/978-3-030-06067-1_43
[17] Sompayrac l.: How the immune system works. Chichester: Wiley-Blackwell; 2012.
[18] Ferrara J, Abhyankar S, Gilliland D.: Cytokine storm of graft-versus-host disease: a critical effector role for interleukin- 1. Transplant Proc. 1993;25:1216–7.
[19] Trásy D, Tánczos K, Németh M et al.: Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients. A prospective observational study. J Crit Care. 2016;34:50–5.
[20] László I, Trásy D, Molnár Z, Fazakas J: Sepsis: from pat 2015;2015:510436.
[21] Nakada T, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe r: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. 4:5–6.
[22] Honore PM, Jamez J, Wauthier M, et al.: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28:3581–7.
[23] Peng Z, Simon P, rimmelé T, Clermont G, Kellum JA: Blood purification in sepsis: a new paradigm. Contrib Nephrol. 2010;65:322–8.
[24] rimmelé T, Kellum JA: Clinical review: blood purification for sepsis. Crit Care. 2011;15:1–10.
[25] Cole L, Bellomo r, Journois D, Davenport P, Baldwin I, Tipping P: High-volume haemofiltration in human septic shock. Crit Care Med. 2001;27:978–86.
[26] Joannes-Boyau O, Bagshaw SM, Dewitte A, Spapen HD, Ouattara A: High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIrE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39:1535–46.
[27] Vincent J, Cohen J, Burchardi H, et al.: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intraabdominal infection. Shock. 2005;23:400–5.
[28] Cruz DN, Antonelli M, Fumagalli r et al.: Early use of polymyxin b hemoperfusion in abdominal septic shock. JAMA. 2009;301:2445.
[29] Payen DM, Lukaszewicz AC, Joannes-Boyau O, Martin- Lefevre L, Kipnis E: Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975–84.
[30] Coudroy r, Payen D, Launey Y, et al.: Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis. Shock. 2017;47:93–9.
[31] Dellinger rP, Levy MM, Opal SM, et al.: Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med. 2013;39:165–228.
[32] Cytosorbent Corporation. CytoSorb® fields of application. http://cytosorb-therapy.com/thetherapy/fields-of-application. Megtekintve 2018 nov. 18.
[33] Bonavia A, Karamchandani K: Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review. Blood Purif. 2018;17033:337–49.
[34] Taniguchi T. Cytokine adsorbing columns. Contrib Nephrol. 2010;166:134–41.
[35] Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemo – adsorption by CytoSorb® in septic patients: a case series. Crit Care. 2017;21:1–10.
[36] ronco C, Brendolan A, Dan M et al: Adsorption in sepsis. Kidney Int. 2000;58:148–55. 36. Peng ZY, Wang HZ, Carter MJ et al: Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81:363–9.
[37] Kellum J, Kong L, Fink MP et al: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–63.
[38] Frimmel S, Schipper J, Henschel J, Tsui TY, Mitzner Sr, Koball S: First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection. Liver Transpl. 2014;20: 1523–4.
[39] Hetz H, Berger r, recknagel P, Steltzer H: Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs. 2014;37:422–6.
[40] Basu r, Pathak S, Goyal J, Chaudhry r, Goel rB, Barwal A: Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: a case study. Indian J Crit Care Med. 2014;18:822–4.
[41] Wiegele M, Krenn CG. Cytosorb™ in a patient with legionella pneumonia-associated rhabdomyolysis: a case report. ASAIO J. 2015;61:18–20.
[42] Wilhelm MJ, Pratschke J, Beato F et al.: Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation. 2000;102:2426–33.
[43] Kellum JA, Venkataraman r, Powner D, Elder M, Her – genroeder G, Carter M: Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36:268–72.
[44] Schädler D, Pausch C, Heise D et al: The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One. 2017;12:1–19.
[45] Hawchar F, Öveges N, László I et al: Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172-178.
[46] Friesecke S, Träger K, Schittek GA et al: International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results. Medi Klin Intensivmed Notfallmed. 2017;
[47] Becze Z, Molnár Z, Fazakas J: Can procalcitonin levels indicate the need for adjunctive therapies in sepsis ? Int J Antimicrob Agents. 2015;46:S13–8.
[48] Trásy D, Molnár Z: Procalcitonin—assisted antibiotic strategy in sepsis. EJIFCC. 2017;28:104–13.
[49] David S, Thamm K, Schmidt BMW, Falk CS, Kielstein JT: Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care. 2017;5:1–5.
[50] Morris C, Gray L, Giovannelli M: Early report: the use of Cytosorb TM haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations. J Intensive Care Soc. 2015;16:257– 64.